T. Rowe Price Associates’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

T. Rowe Price Associates’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-1,037,935	Closed	-$101M	–	2595
2015 Q1	$101M	Buy	1,037,935 +547,235	+112%	+$57.9M	0.02%	607
2014 Q4	$45.5M	Buy	490,700 +484,100	+7,335%	+$38.2M	0.01%	873
2014 Q3	$454K	Buy	6,600 +1,000	+18%	+$71.6K	﹤0.01%	1981
2014 Q2	$587K	Buy	5,600 +900	+19%	+$76.6K	﹤0.01%	1880
2014 Q1	$390K	Hold	4,700	–	–	﹤0.01%	2023
2013 Q4	$304K	Buy	+4,700	New	+$279K	﹤0.01%	2137

T. Rowe Price Associates's GEVA Position: Q2 2015 in Review

T. Rowe Price Associates sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 1,037,935 shares — an estimated $101M sold.

T. Rowe Price Associates first reported a position in GEVA in Q4 2013 and held it in 6 quarters. The position peaked at $101M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

T. Rowe Price Associates reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
T. Rowe Price Associates sold 1,037,935 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $101M.
T. Rowe Price Associates first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q4 2013 and held it in 6 quarters.
T. Rowe Price Associates's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $101M in Q1 2015.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on T. Rowe Price Associates's 13F filing for Q2 2015, filed 14 Aug 2015.